Journey Medical (DERM) Expected to Announce Earnings on Wednesday

Journey Medical (NASDAQ:DERM) is expected to be posting its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect Journey Medical to post earnings of ($0.07) per share and revenue of $15.4730 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:30 PM ET.

Journey Medical (NASDAQ:DERM) last released its earnings results on Wednesday, March 25th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. Journey Medical had a negative net margin of 18.48% and a negative return on equity of 46.40%. The company had revenue of $16.08 million for the quarter, compared to the consensus estimate of $18.86 million. On average, analysts expect Journey Medical to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Journey Medical Stock Up 1.2%

Journey Medical stock opened at $5.18 on Wednesday. The company has a quick ratio of 1.53, a current ratio of 1.79 and a debt-to-equity ratio of 0.79. Journey Medical has a 12-month low of $4.31 and a 12-month high of $9.56. The firm’s fifty day moving average is $6.28 and its 200 day moving average is $7.41. The company has a market capitalization of $141.57 million, a PE ratio of -11.02 and a beta of 1.03.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Bank of America Corp DE raised its holdings in Journey Medical by 4,707.0% during the second quarter. Bank of America Corp DE now owns 4,134 shares of the company’s stock worth $30,000 after buying an additional 4,048 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Journey Medical during the second quarter worth $36,000. JPMorgan Chase & Co. acquired a new position in Journey Medical during the second quarter worth $41,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Journey Medical during the second quarter worth $48,000. Finally, Russell Investments Group Ltd. acquired a new position in Journey Medical during the third quarter worth $61,000. Institutional investors and hedge funds own 7.25% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Journey Medical in a research report on Monday, April 20th. HC Wainwright reiterated a “buy” rating and set a $13.00 target price on shares of Journey Medical in a research report on Thursday, March 26th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $13.00.

Journey Medical Company Profile

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company’s product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.